NASDAQ$NRC

NRC Health · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Announced first quarter results.

NRC Health announced its first quarter 2024 results, highlighting investments in technology, sales, and service teams to launch new products and solutions. The company returned $18 million to stockholders through dividends and stock repurchases and invested $4 million in organic innovation and growth.

  • NRC is positioned for growth due to benchmarks and trusted thought leadership.
  • The company is launching an expanded product suite to address consumer, patient, and caregiver experiences.
  • New AI features and solutions are expected to be offered and integrated across products and business.
  • The company expects to continue building AI and technology capabilities, sales, and thought leadership resources while seeking operating efficiencies.

Headline financials

Total Revenue

$35.3M

Previous: $36.5M-3.2%
EPS

$0.27

Previous: $0.28-3.6%
Capital Expenditures

-$4.14M

Previous: -$3.2M-29.4%
Free Cash Flow

$2.22M

Previous: $3.77M-41.0%
Net Income

$6.36M

Previous: $6.96M-8.7%
Operating Income

$8.76M

Previous: $9.02M-2.8%
Gross Profit

-$13.9M

Previous: -$14.3M+3.0%
Cash & Equivalents

$1.7M

Previous: $23.7M-92.8%
Total Assets

$121M

Previous: $134M-10.0%
Stock-Based Comp

-$36K

Previous: $304K-111.8%

Revenue & EPS history

NRC · Revenue · Quarterly

$35.3M

Q1 2024-3.2%vs Q1 2023

Forward guidance

The company anticipates ongoing investment in AI and technology capabilities, alongside sales and thought leadership resources, with a focus on achieving operational efficiencies.

Tailwinds

  • Roll out of new products.
  • Thought leadership assets.
  • Future use of AI.
  • Investment in product innovation.
  • Investment in sales, technology, and thought leadership resources.

Headwinds

  • Operating efficiency.
  • Client profitability.
  • Potential to expand Human Understanding.
  • Increase market share.
  • Future revenue growth.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-0.9%

Avg return

Earnings day

-0.9%

Avg return

5 days after

-0.3%

Avg return

30 days after

54%

28 / 52 earnings

Positive

+16.1%

Q3 2025

Best reaction

-19.9%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.6%+7.9%+16.0%
Q4 2025-19.9%-27.2%-35.9%
Q3 2025+16.1%+17.0%+51.2%
Q2 2025+2.1%+4.8%+6.7%
Q1 2025+7.0%+7.6%+20.2%
Q4 2024-11.9%-11.0%-22.6%
Q3 2024+2.6%-2.1%+4.5%
Q2 2024-11.7%-9.3%-7.2%
Q1 2024-15.3%-11.6%-23.7%
Q4 2023+2.2%+0.6%+1.7%
Q3 2023-1.9%-0.3%-1.1%
Q2 2023+2.2%-0.4%-2.6%
Q1 2023-8.3%-5.2%-1.2%
Q4 2022+4.8%+5.3%-1.8%
Q3 2022-13.5%-8.3%-3.5%
Q2 2022-4.1%-7.4%-12.8%
Q1 2022-5.3%-3.6%+5.0%
Q4 2021-1.5%-4.5%-4.7%
Q3 2021+6.7%+6.7%-8.1%
Q2 2021-0.8%-0.2%+1.6%
Q1 2021-10.2%-5.1%-7.0%
Q4 2020-0.7%-3.9%+0.3%
Q3 2020+1.8%-0.1%-7.8%
Q2 2020-4.1%-1.0%-3.0%
Q1 2020+4.6%+10.3%+12.7%
Q4 2019+0.3%+1.8%-36.0%
Q3 2019-0.4%+0.2%+7.5%
Q2 2019+3.0%+2.6%+1.0%
Q1 2019+7.1%+13.1%+26.5%
Q4 2018+0.6%+2.7%+0.2%
Q3 2018+3.5%+2.4%+4.8%
Q2 2018-0.3%-0.3%+2.4%
Q1 2018+7.3%+5.5%+5.4%
Q4 2017-7.4%-7.9%-9.7%
Q3 2017-10.1%-11.5%-7.7%
Q2 2017+0.9%+1.7%+9.9%
Q1 2017+0.8%-3.4%-3.0%
Q4 2016-3.0%-4.9%+0.5%
Q3 2016-4.6%-1.0%+5.2%
Q2 2016+0.3%+2.3%+2.2%
Q1 2016+2.0%
Q4 2015+0.6%
Q3 2015+1.5%
Q2 2015-2.4%
Q1 2015+1.3%
Q4 2014-0.8%
Q3 2014+0.9%
Q2 2014+3.8%
Q1 2014+3.9%
Q4 2013+5.1%
Q3 2013+1.0%
Q2 2013-1.2%
Q1 2013
Q4 2012
Q2 2010
Q3 2012
Q2 2012
Q1 2012
Q4 2011
Q1 2011
Q3 2011
Q3 2010
Q4 2009
Q2 2011
Q4 2010
Q1 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro